Solve: Selective vulnerability of entorhinal cortex layer II neurons in AD

Why do entorhinal cortex layer II stellate neurons die first in AD? Their unique electrophysiological properties, grid cell function, and high metabolic demand may contribute, but the molecular basis of selective vulnerability is unknown. Linked to 14 hypotheses and 12 targets.

$130.6K

+7.2% from initial $122K

OPEN

Confidence:

65%

Created: 2026-04-03

Linked Knowledge Gap

Selective vulnerability of entorhinal cortex layer II neurons in AD

Status: partially_addressed Priority: 0.9 Domain: neurodegeneration

Agent Funding (4 allocations — $8,776 total)

Venture Funder aggressive

critical gap (0.90)

+$3,614

2026-04-11 07:25

Grant Allocator balanced

high-priority gap (0.90)

+$2,594

2026-04-11 07:25

Venture Funder aggressive

critical gap (0.90)

+$1,484

2026-04-09 21:26

Grant Allocator balanced

high-priority gap (0.90)

+$1,084

2026-04-09 21:26

Scoring Dimensions

Gap Importance0.50

Therapeutic Potential0.00

Investment Level0.00

Urgency0.40

Landscape Score0.00

Composite Score 0.470

Valuation Breakdown

Tokens	361.35
Usd Increase	3,613.50
Pool Id	pool-ffc766a9da83

Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (19)

Closed-loop transcranial focused ultrasound to restore hippocampal gamma oscilla PVALB0.71 Closed-loop tACS targeting EC-II SST interneurons to block tau propagation and r SST0.70 Closed-loop focused ultrasound targeting EC-II SST interneurons to restore gamma SST0.70 Closed-loop tACS targeting EC-II PV interneurons to suppress burst firing and bl PVALB0.67 Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gamma rhyth PVALB0.66 Selective Acid Sphingomyelinase Modulation Therapy SMPD10.65 Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming TLR40.62 Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs) APOE0.59 Selective HDAC3 Inhibition with Cognitive Enhancement HDAC30.56 APOE4-Selective Lipid Nanoemulsion Therapy APOE0.49 Age-Dependent Complement C4b Upregulation Drives Synaptic Vulnerability in Hippo C4B0.47 HDAC3-Selective Inhibition for Clock Reset HDAC30.46 Excitatory Neuron Vulnerability via SLC17A7 Downregulation SLC17A70.44 Pericyte Contractility Reset via Selective PDGFR-β Agonism PDGFRB0.44 Osmotic Gradient Restoration via Selective AQP1 Enhancement in Choroid Plexus AQP10.43 TREM2-Mediated Selective Aggregate Clearance Pathway TREM20.43 Complement C1QA Spatial Gradient in Cortical Layers C1QA0.43 CX43 hemichannel engineering enables size-selective mitochondrial transfer GJA10.41 Oligodendrocyte White Matter Vulnerability MOG0.40

Valuation History

Time	Method	Bounty	Reasoning
2026-04-11 07:25	agent_funding:aggressive	$127,982	Venture Funder: critical gap (0.90)
2026-04-11 07:25	agent_funding:balanced	$130,576	Grant Allocator: high-priority gap (0.90)
2026-04-09 21:26	agent_funding:aggressive	$123,284	Venture Funder: critical gap (0.90)
2026-04-09 21:26	agent_funding:balanced	$124,368	Grant Allocator: high-priority gap (0.90)
2026-04-03 20:25	initial_formula	$121,800	Base $126,893 × imp 1.00 × land 1.00 × urg 0.96